Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03570931 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
A Phase 2 study of Infantile Neuroaxonal Dystrophy, sponsored by Biojiva.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT03570931 is a Phase 2 study of Infantile Neuroaxonal Dystrophy that is active but no longer recruiting, run by Biojiva. The registered enrollment target is 19 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03570931, a Phase 2 study of Infantile Neuroaxonal Dystrophy, is active but no longer recruiting, sponsored by Biojiva.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD).
Conditions Studied
Interventions
- DRUG RT001
Study Locations (2)
California
- University of California San Francisco, Benioff Children's Hospital - San Francisco
New Jersey
- Jacobs Levy Genomics and Research Program - Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03570931
The ClinicalTrials.gov registry entry for NCT03570931 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biojiva, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infantile Neuroaxonal Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which RT001 is the first listed.
NCT03570931 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03570931 about?
NCT03570931 is a clinical study titled "A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy". The purpose of this study is to evaluate the efficacy and safety of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD).
What is the current status of trial NCT03570931?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-11-05. Estimated completion is 2022-06-30.
What conditions does trial NCT03570931 study?
This clinical trial studies the following conditions: Infantile Neuroaxonal Dystrophy.
What interventions are being tested in trial NCT03570931?
The interventions under investigation include: RT001 (DRUG).
Who is sponsoring clinical trial NCT03570931?
This trial is sponsored by Biojiva, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03570931 being conducted?
This trial has 2 study locations across California, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.